Tumor necrosis factor receptor 2 gene (TNFRSF1B) in genetic basis of coronary artery disease

被引:54
作者
Benjafield, AV
Wang, XL
Morris, BJ
机构
[1] Univ Sydney, Dept Physiol, Basic & Clin Genom Lab, Sydney, NSW 2006, Australia
[2] Univ Sydney, Biomed Res Inst, Sydney, NSW 2006, Australia
[3] Univ New S Wales, Prince Wales Hosp, Ctr Thrombosis & Vasc Res, Cardiovasc Genet Lab, Sydney, NSW, Australia
[4] SW Fdn Biomed Res, Dept Genet, San Antonio, TX 78245 USA
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 2001年 / 79卷 / 2-3期
基金
英国医学研究理事会;
关键词
tumor necrosis factor receptor; tumor necrosis factor receptor superfamily member 1B gene; coronary artery disease; genetic polymorphism; case-control study;
D O I
10.1007/s001090000168
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Tumor necrosis factor (TNF)-alpha has been implicated in pathophysiological processes in coronary artery disease (CAD). TNF receptor 2 is of particular interest in mediating such effects. The gene for this receptor (TNF-RSFIB) has, moreover, been implicated in hypertension, elevated cholesterol and insulin resistance. TNFRSFIB is thus a worthy candidate in studies of the genetic basis of CAD. We therefore conducted a case-control study of a microsatellite marker with five alleles (CA13-CA17) in intron 4 of TNFRSFIB in 1006 well-characterized white patients with angiographically confirmed CAD and a control group of 183 healthy subjects. We found a strong association of the TNFRSFIB marker with CAD (chi (2)=40, P=0.00000069). The frequency of the CA16 allele was 33% in CAD vs. 21% in control (odds ratio, OR, to have CAD for presence vs, absence of CA16 allele in CA16 homozygotes was 4.5, 95% CI 2.1-9.4, P <0.0001; in CA16 heterozygotes OR was 1.3, 95% CI 0.94-1.89, P=0.10). The frequency of the major allele (CA15) was 43% in CAD vs, 56% in controls (in CA15 homozygotes OR 0.33, 95% CI 0.20-0.52, P <0.0001; in heterozygotes OR 0.41, 95% CI 0.26-0.63, P <0.0001). In a stepwise logistic regression model the CA16 allele was significantly associated with overweight (OR 1.44, 95% CI 1.0-1.9, P=0.027). Apolipoprotein A-I was elevated (P <0.0001), as was high-density lipoprotein (P=0.098), and severity of angina was decreased (P=0.024) as a function of genotype. Plasma soluble (s) TNF-R2 was 5.1 +/-0.1 ng/ml in CAD vs. 3.2 +/-0.1 in control (P<0.0001), 5.2<plus/minus>0.1 in the presence vs. 4.6 +/-0.2 in the absence of vessel disease (P=0.009), and rose with increasing severity of angina: 4.2 +/-0.2 (no angina), 5.0 +/-0.1 (stable angina), 5.4 +/-0.2 (unstable angina; P=0.003), sTNF-R2 was correlated with age, cholesterol, creatinine, fibrinogen, transforming growth factor P and homocysteine and was influenced by TNFRSFIB genotype. Thus genetic variation in or near the TNFRSFIB locus may predispose to CAD.
引用
收藏
页码:109 / 115
页数:7
相关论文
共 46 条
  • [1] STABILIZATION OF THE BIOACTIVITY OF TUMOR-NECROSIS-FACTOR BY ITS SOLUBLE RECEPTORS
    ADERKA, D
    ENGELMANN, H
    MAOR, Y
    BRAKEBUSCH, C
    WALLACH, D
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1992, 175 (02) : 323 - 329
  • [2] Alsalameh S, 1999, J RHEUMATOL, V26, P645
  • [3] Physical mapping and genomic structure of the human TNFR2 gene
    Beltinger, CP
    White, PS
    Maris, JM
    Sulman, EP
    Jensen, SJ
    LePaslier, D
    Stallard, BJ
    Goeddel, DV
    deSauvage, FJ
    Brodeur, GM
    [J]. GENOMICS, 1996, 35 (01) : 94 - 100
  • [4] BLACKBURN WD, 1991, J LIPID RES, V32, P1911
  • [5] Increased levels of soluble tumor necrosis factor receptors in atherosclerosis: No clear relationship with levels of tumor necrosis factor
    Blann, AD
    McCollum, CN
    [J]. INFLAMMATION, 1998, 22 (05) : 483 - 491
  • [6] ANTITUMOR NECROSIS FACTOR-ALPHA TREATMENT INTERFERES WITH CHANGES IN LIPID-METABOLISM IN A TUMOR CACHEXIA MODAL
    CARBO, N
    COSTELLI, P
    TESSITORE, L
    BAGBY, GJ
    LOPEZSORIANO, FJ
    BACCINO, FM
    ARGILES, JM
    [J]. CLINICAL SCIENCE, 1994, 87 (03) : 349 - 355
  • [7] Tumor necrosis factor in congestive heart failure: A mechanism of disease for the new millennium?
    Ceconi, C
    Curello, S
    Bachetti, T
    Corti, A
    Ferrari, R
    [J]. PROGRESS IN CARDIOVASCULAR DISEASES, 1998, 41 (01) : 25 - 30
  • [8] Genetic epidemiology of single-nucleotide polymorphisms
    Collins, A
    Lonjou, C
    Morton, NE
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (26) : 15173 - 15177
  • [9] Safety and efficacy of a soluble P75 tumor necrosis factor receptor (enbrel, etanercept) in patients with advanced heart failure
    Deswal, A
    Bozkurt, B
    Seta, Y
    Parilti-Eiswirth, S
    Hayes, FA
    Blosch, C
    Mann, DL
    [J]. CIRCULATION, 1999, 99 (25) : 3224 - 3226
  • [10] TUMOR NECROSIS FACTOR STIMULATES HEPATIC LIPID-SYNTHESIS AND SECRETION
    FEINGOLD, KR
    SERIO, MK
    ADI, S
    MOSER, AH
    GRUNFELD, C
    [J]. ENDOCRINOLOGY, 1989, 124 (05) : 2336 - 2342